Anakoinosis Publications

1) A Computational Model of Tumor Growth and Anakoinosis. Pantziarka P, Ghibelli L, Reichle A. Front Pharmacol. 2019 Mar 26;10:287. doi: 10.3389/fphar.2019.00287. eCollection 2019. PMC6444062

2) Re-establishing Apoptosis Competence in Bone Associated Cancers via Communicative Reprogramming Induced Through Notch Signaling Inhibition. Front Pharmacol. 2019 Feb 27;10:145. doi: 10.3389/fphar.2019.00145. eCollection 2019. Review. PMC6400837

3) Clinical Efficacy of a Novel Therapeutic Principle, Anakoinosis. Heudobler D, Rechenmacher M, Lüke F, Vogelhuber M, Klobuch S, Thomas S, Pukrop T, Hackl C, Herr W, Ghibelli L, Gerner C, Reichle A. Front Pharmacol. 2018 Nov 28;9:1357. doi: 10.3389/fphar.2018.01357. eCollection 2018. Review. PMC6279883

4) Lowering Etoposide Doses Shifts Cell Demise From Caspase-Dependent to Differentiation and Caspase-3-Independent Apoptosis via DNA Damage Response, Inducing AML Culture Extinction.Bruni E, Reichle A, Scimeca M, Bonanno E, Ghibelli L. Front Pharmacol. 2018 Nov 13;9:1307. doi: 10.3389/fphar.2018.01307. eCollection 2018. PMC6243040

5) Cutaneous Leukemic Infiltrates Successfully Treated With Biomodulatory Therapy in a Rare Case of Therapy-Related High Risk MDS/AML. Heudobler D, Klobuch S, Thomas S, Hahn J, Herr W, Reichle A. Front Pharmacol. 2018 Nov 13;9:1279. doi: 10.3389/fphar.2018.01279. eCollection 2018. PMC6243099

6) Peroxisome Proliferator-Activated Receptors (PPAR)γ Agonists as Master Modulators of Tumor Tissue. Heudobler D, Rechenmacher M, Lüke F, Vogelhuber M, Pukrop T, Herr W, Ghibelli L, Gerner C, Reichle A. Int J Mol Sci. 2018 Nov 9;19(11). pii: E3540. doi: 10.3390/ijms19113540. Review. PMC6274845

7) Metronomics: Intrinsic Anakoinosis Modulator? Nicolas A, Carré M, Pasquier E. Front Pharmacol. 2018 Jun 25;9:689. doi: 10.3389/fphar.2018.00689. eCollection 2018. No abstract available. PMC6026805

8) Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial.Walter I, Schulz U, Vogelhuber M, Wiedmann K, Endlicher E, Klebl F, Andreesen R, Herr W, Ghibelli L, Hackl C, Wiest R, Reichle A. Med Oncol. 2017 Nov 2;34(12):192. doi: 10.1007/s12032-017-1040-0. PMC5668342

9) Anakoinosis: Communicative Reprogramming of Tumor Systems – for Rescuing from Chemorefractory Neoplasia.Hart C, Vogelhuber M, Wolff D, Klobuch S, Ghibelli L, Foell J, Corbacioglu S, Rehe K, Haegeman G, Thomas S, Herr W, Reichle A. Cancer Microenviron. 2015 Aug;8(2):75-92. doi: 10.1007/s12307-015-0170-1. Epub 2015 Aug 11. PMC4542828